• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

ben.tran@unimelb.edu.au

Credentials


Position
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
ORCID

0000-0001-9124-354X

Prof Ben Tran

Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology

471 Scholarly works
11 Projects

HIGHLIGHTS

  • 2026

    Journal article

    A roadmap for establishing institutional readiness for cellular therapies targeting solid tumours and autoimmune diseases
    DOI: 10.1038/s41698-026-01462-6
  • 2026

    Journal article

    Treatment Patterns and Survival Outcomes in a Real-World Cohort of Lutetium 177 Vipivotide Tetraxetan (LuPSMA)-Experienced Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)
    DOI: 10.1016/j.clgc.2026.102609
  • 2026

    Journal article

    Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial
    DOI: 10.1016/S1470-2045(26)00194-4
  • 2026

    Journal article

    Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
    DOI: 10.1158/1078-0432.CCR-25-3447
  • 2022

    Research grants (ARC, NHMRC, MRFF)

    Targeting Cold Tumours With Triple Therapy
  • 2019

    Research Grant

    PRECEPT - PRostatE CancEr Prognosis and Treatment
  • 2017

    Research Grant

    Combination of Radionuclide 177lu-Psma Therapy With Pembrolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer (Mcrpc)
Ben Tran

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma.
    DOI: 10.1038/s41467-026-74255-x
  • 2026

    Journal article

    Advances in cancer immunotherapy: adoptive cell therapy and immune cell engagers in solid tumours
    DOI: 10.1038/s41416-026-03450-w
  • 2026

    Journal article

    A simple plan: chemotherapy-sparing approaches to early-stage and regional seminoma and nonseminoma
    DOI: 10.1016/j.annonc.2026.04.005
  • 2026

    Journal article

    Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials
    DOI: 10.1016/j.eururo.2026.03.024
  • 2026

    Journal article

    The Australian Penile Cancer Clinical Registry: a comprehensive national approach to data collection
    DOI: 10.1111/bju.70188
  • 2026

    Journal article

    177RO Regulatory approval delays for pembrolizumab and trastuzumab deruxtecan across the Asia-Pacific region
    DOI: 10.1016/j.esmoop.2026.107978

RECENT PROJECTS

  • 2024

    Research grants (other domestic)

    Stereotactic Ablative Body Radiotherapy (SABR) for 4 Gynaecologic Metastases
  • 2024

    Research grants (ARC, NHMRC, MRFF)

    P3BEP Trial - Accelerating First-Line Chemotherapy to Improve Cure Rates for Advanced Germ Cell Tumours - An Australian-Led, International Randomised Trial

Acknowledgement of Country

We acknowledge Aboriginal and Torres Strait Islander people as the Traditional Owners of the unceded lands on which we work, learn and live. We pay respect to Elders past, present and future, and acknowledge the importance of Indigenous knowledge in the Academy.

Read about our Indigenous priorities

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Campus locations  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia

facebookIconlinkedinIconinstagramIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy

CRICOS number: 00116K     ABN: 84 002 705 224